GleamWall
中文EN

NMAD NOMAD POWER SOLUTIONS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1335105 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-474.2%
TTM EPS YoY-283.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-39.2%
ROA-31.9%
ROIC (approx.)-35.2%
Asset turnover—

Leverage & solvency

Liabilities / assets17.9%
Debt / equity0.00x
Current ratio0.78x
Interest coverage-191.93x

Cash quality & payout

Operating cash flow / net income0.46x
Accruals ratio-17.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$254,919$726,232
SG&A expense$4.85M$2.85M
Operating income-$5.11M-$3.57M
Interest expense$9,158$16,821
Income tax$1,600—
Net income-$6.08M-$3.59M
EPS (basic)—-1.59
EPS (diluted)-1.26-1.59
Weighted avg. shares (diluted)4.84M2.25M
Balance sheet
Cash & equivalents$156,000$1.04M
Receivables$529,000—
Inventory$6.67M—
Current assets$8.39M$1.15M
PP&E, net$474,000—
Intangibles$147,000—
Total assets$11.91M$1.15M
Current liabilities$18.05M$318,284
Short-term debt$1.14M—
Long-term debt$5.47M—
Total debt$6.61M—
Total liabilities$23.66M$318,284
Shareholders' equity-$11.75M$827,219
Net debt$6.45M—
Shares outstanding1.11M2.25M
Cash flow statement
Operating cash flow-$3.07M-$3.16M
Investing cash flow-$3.17M—
Financing cash flow$10.31M—
Stock-based compensation$1.39M$418,422

Free plan shows the latest 2 periods; Pro shows all 20 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.